Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Japan Clinical Oncology Group
With
Ministry of Health, Labour and Welfare, Japan
The purpose of this study is to evaluate whether radiotherapy with carboplatin will result in longer survival than radiotherapy alone in elderly patients with unresectable stage III NSCLC.
Age
71–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically and/or cytologically proven NSCLC
Unresectable disease
Stage IIIA except T3N1M0 and IIIB which does not have disease extended to any contralateral hilar nodes, atelectasis of the entire lung or malignant pleural effusions
A required radiation field of less than one half of one lung
Measurable disease
No previous chemotherapy or radiotherapy
Age \>= 71
Unable to receive cisplatin-based combination chemotherapy
ECOG performance status (PS) of 0-2
Adequate bone marrow, lung, hepatic, and renal function
Written informed consent
You may not be if
Active infection, diarrhea, ileus, uncontrolled diabetes, myocardial infarction within three months, or severe other comorbidity
Synchronous cancer or metachronous (within 5 years) malignancy
Interstitial pneumonia or active lung fibrosis on chest X-ray
Severe chronic obstructive pulmonary disease, chronic bronchitis, or bronchial asthma
Pleural or pericardial effusion
A history of severe hypersensitivity
Mental disorder
Judging of inappropriate condition for this study by physician
Clareo Health | Trial to Evaluate Radiotherapy With or Without CBDCA in Elderly Patients With Non-Small Cell Lung Cancer (JCOG0301)
